China NT Pharma Group Company Limited provided earnings guidance for the six months ended June 30, 2012. The board currently estimates that the Group could possibly record a loss for the six months ended 30 June 2012. The loss is attributable to the company's business restructuring measures introduced during the period in order to enhance its competitiveness and to improve cash flow, which involved gradual exiting from its vaccine and pharmaceutical supply chain business and downsizing of its vaccine sales and promotion team, and the resulting expenses incurred.